Drug Related Products

(SLXP) Positive Data on Roche Candidate

Roche (RHHBY) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124).

The study is evaluating the efficacy and safety of etrolizumab...

21Aug2013 | | Comments Off on (SLXP) Positive Data on Roche Candidate | Continued

(SLXP) Mixed Quarter from Salix Pharmaceuticals

Salix Pharmaceuticals, Ltd. (SLXP) posted third quarter earnings of 95 cents per share, well above the Zacks Consensus Estimate of 64 cents, the year-ago earnings of 77 cents and the company’s earnings guidance of 69 cents per share....

28Nov2012 | | Comments Off on (SLXP) Mixed Quarter from Salix Pharmaceuticals | Continued

(PRGO) Perrigo Cut to Neutral

We have downgraded Perrigo Company (PRGO) to Neutral from Outperform following the disappointing revenue numbers put out by the company in the fourth quarter of fiscal 2012 (ended June 30, 2012). The stock carries a Zacks #3 Rank...

18Sep2012 | | Comments Off on (PRGO) Perrigo Cut to Neutral | Continued

(PRGO) Perrigo Analyst Maintains Neutral Share rating

We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results.

Perrigo reported second quarter EPS of $1.20, beating the Zacks Consensus...

24Feb2012 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals – Bull of the Day

Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for...

28Nov2011 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals – Bull of the Day

Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for...

28Nov2011 | | 0 comments | Continued

(PRGO) Perrigo Company – Bull of the Day

Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of $0.87. Perrigo upped fiscal 2012 earnings per share outlook...

17Nov2011 | | 0 comments | Continued

(PRGO) Perrigo Beats Earnings Forecast – Sales Miss

Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset...

2Nov2011 | | 0 comments | Continued

(PRGO) Perrigo Downgraded to Neutral

We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00.

Perrigo’s broad line of store brand pharmaceutical products has the same active ingredients and comparable...

10Jul2011 | | 0 comments | Continued

(PRGO) Perrigo Cruises Past Estimates – Lifts Outlook

Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by...

8May2011 | | 0 comments | Continued

(PRGO) Perrigo Resolves Manufacturing Issues with FDA

Perrigo Company (PRGO) recently announced the resolution of manufacturing issues at its Allegan, Michigan facility with the US Food and Drug Administration (FDA) following conclusion of re-inspection of the facility by the agency....

13Apr2011 | | 0 comments | Continued

(AUXL) Auxilium Pharmaceuticals Reports Narrower Loss

Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 35 cents. Higher revenues helped the company post...

24Nov2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals Posts Narrower Third Quarter 2010 Loss

Salix Pharmaceuticals, Ltd. (SLXP) posted a loss of 5 cents per share in the third quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the guidance provided by the company (loss of 13 cents). Salix...

17Nov2010 | | 0 comments | Continued

(PRGO) Perrigo Company – Earnings Estimates Jump

Perrigo Company (PRGO) recently hit a new multi-year high at $64.66 after reporting a solid Q3 earnings surprise of 21% in late April. Estimates are on the upswing and shares are trading in line with their industry peers.

Company...

20May2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals Exceeds Consensus Estimates

Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 45 cents per share in the first quarter of 2010, 6 cents better than the Zacks Consensus Estimate. The company had guided towards a net loss of 50 cents. Salix reported a net...

17May2010 | | 0 comments | Continued

(AUXL) Auxilium Pharmaceuticals Reports Quarterly Loss That Narrows

Strong Testim sales helped Auxilium Pharmaceuticals, Inc. (AUXL) report a narrower-than-expected net loss of 18 cents per share in the first quarter of 2010, 13 cents below the Zacks Consensus Estimate and year-ago net loss of 31...

6May2010 | | 0 comments | Continued

(HLF) Herbalife Incorporated – Earnings Estimates Up

Herbalife, Inc. (HLF) recently hit a new 52-week high above $47 after shares jumped above a short-term level of resistance on strong Q4 results from late February and a bullish next-year estimate.

Fourth-Quarter Results

Shares...

5Apr2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals Earns FDA Approval for Xifaxan

Salix Pharmaceuticals, Ltd. (SLXP) received a huge boost recently with the US approval of Xifaxan 550 mg. The Food and Drug Administration (FDA) granted approval for the use of Xifaxan 550 mg in reducing the risk of the recurrence...

29Mar2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals Beats Forecasts but Outlook Disappoints

Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 13 cents per share in the fourth quarter, a penny better than the Zacks Consensus Estimate and company guidance of a net loss of 14 cents. Salix reported a net loss of 12 cents...

10Mar2010 | | 0 comments | Continued

(HLF) Herbalife – Return on Equity of 64.8% is Far Ahead of Industry Average

Herbalife (HLF) is expected to grow its earnings per share at 13.5% for the next five years. This Zacks Rank #2 stock also pays a decent dividend.

Company Description

Herbalife Ltd. is a global network marketing...

10Mar2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals Focuses on Label Expansion

Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents. For the full year, the Zacks...

8Mar2010 | | 0 comments | Continued

(NTY) NBTY Incorporated – Reports Record First Quarter Results

NBTY Inc. (NTY) recently surprised on estimates for the fourth quarter in a row as sales hit a first quarter record. NBTY has a forward P/E of just 11.9.

Company Description

NBTY manufactures and distributes...

3Mar2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals Gets Good News From FDA

Salix Pharmaceuticals, Ltd. (SLXP) received good news recently when the Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee recommended the approval of Xifaxan (500 mg) for the maintenance of remission...

1Mar2010 | | 0 comments | Continued

(AUXL) Auxilium Pharmaceuticals’ Xiaflex Awarded FDA Approval

Auxilium Pharmaceuticals, Inc. (AUXL) recently received a major boost when the U.S. Food and Drug Administration (FDA) granted approval to Xiaflex for the treatment of adult Dupuytren’s contracture patients with a palpable cord....

3Feb2010 | | 0 comments | Continued

(AUXL) Auxilium Pharmaceuticals and Pfizer Announces EU Review Process

Auxilium Pharmaceuticals, Inc. (AUXL) and Pfizer Inc. (PFE) recently announced that the review process of their Marketing Authorization Application (MAA) for Xiaflex...

25Jan2010 | | 0 comments | Continued

(NTY) NBTY Incorporated – Consensus Earnings Estimates Jump

NBTY Inc. (NTY) recently announced preliminary fiscal first-quarter results which showed sales jumped 14%. The company has a PEG ratio of just 0.90 and is trading at 12.6x forward earnings.

Company Description

NBTY...

15Jan2010 | | 0 comments | Continued

(HLF) Herbalife Limited – Return on Equity of 65% Beats Industry Average of 15%

Herbalife Ltd. (HLF) has more than doubled the market’s return over the past year. Analysts polled by Zacks boosted forecasts on Herbalife’s recent reaffirmation of 2009 and 2010 earnings outlook.

Company...

15Jan2010 | | 0 comments | Continued

(SLXP) Salix Pharmaceuticals to File for IBS Indication

Salix Pharmaceuticals, Ltd. (SLXP) recently held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) related to the company’s new drug application (NDA) for rifaximin for the treatment of patients with non-constipation...

16Dec2009 | | 0 comments | Continued

(PRGO) Perrigo Company – Revenues Spike Year-Over-Year

Perrigo Co. (PRGO) analysts are steadily increasing estimates for the drug company, fueled by the latest earnings surprise.

Company Description

Perrigo Co. makes OTC and generic prescription...

10Dec2009 | | 0 comments | Continued

(HLF) Herbalife Ltd. – Analysts Polled Remain Bullish on Earnings

Herbalife Ltd. (HLF) continues to trade higher, closing in on a 52-week high and outpacing the market since the stock was last featured as a Momentum pick. During the past year, shares soared about 130% past the S&P 500.

Analysts...

7Dec2009 | | 0 comments | Continued